RxDoctor Payments Data

David Scollan, MD

Clinical Cardiac Electrophysiology · West Reading, PANPI 1689735391

Payments from drug & device makers

$3,171in general payments, 2019–2025

Across 151 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$928
  • Atricure, Inc.$567
  • Impulse Dynamics (USA) Inc.$502
  • Pfizer$422
  • ZOLL Respicardia, Inc.$224
  • E.r. Squibb & Sons, L.L.C.$180
  • plus $348 from 8 others

What the payments were for

  • Food & beverage$3,171100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,171 in reported general payments places this provider in the 10th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$254,364
Medicare patients
1,497
Services billed
4,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban435$416,086
XareltoRivaroxaban111$117,814
MultaqDronedarone Hcl41$40,774
EntrestoSacubitril/Valsartan28$35,269
JardianceEmpagliflozin20$23,771
Repatha SureclickEvolocumab27$18,930
FarxigaDapagliflozin Propanediol12$13,291
Dabigatran EtexilateDabigatran Etexilate Mesylate23$7,464
Metoprolol Succinate291$5,422
Flecainide Acetate111$4,290
Rosuvastatin Calcium201$2,787
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$2,522
Amiodarone Hcl134$1,607
Atorvastatin Calcium112$1,607
Ezetimibe70$1,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$422$416,086435 claims
Johnson & JohnsonXarelto$48$117,814111 claims
NovartisEntresto$21$35,26928 claims
AstraZenecaFarxiga$54$13,29112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in West Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →